Global Antibiotic Resistance Market, By Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Others), By Disease (cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection), Others (BSI (Bloodstream infection), etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).
The global antibiotic resistance market was valued US$ 8.83 Bn in 2023 and is expected to reach US$ 13.37 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.
Figure 1. Global Antibiotic Resistance Market Share (%), By Region, 2023
The global antibiotic resistance market has been witnessing significant growth in recent years. Antibiotics are medicines used to prevent and treat bacterial infections. They either kill bacteria or stop them from multiplying. Some of the most commonly used antibiotics include penicillin, amoxicillin, cephalosporins etc. However, over the past few decades, antibiotic resistance has been emerging as a major public health threat globally. When bacteria become antibiotic resistant, the medicines used to treat the infections they cause become ineffective. This leads to longer illness and increased death rates. The rising prevalence of bacterial strains that are resistant to various antibiotic classes is primarily attributable to misuse and overuse of antibiotics. Other factors that drive antibiotic resistance include the lack of development of new antibiotics, lack of sanitation and hygiene in many parts of the world, increased international travels, etc. If not addressed properly, antibiotic resistance could lead to serious health issues and affect patient outcomes.
Market Dynamics:
The global antibiotic resistance market growth is driven by various factors such as increasing prevalence of antibiotic-resistant bacterial infections, lack of new antibiotic development, misuse and overuse of existing antibiotics, limited infection control in many developing regions, etc. However, the development of alternative treatment options and stringent regulations regarding antibiotic usage could restrain the market growth. The market provides opportunities for companies focusing on the development of novel antibiotics with new mechanisms of action. Key players are also exploring alternative therapeutic approaches like phage therapy, vaccines, monoclonal antibodies etc. to counter antibiotic resistance. Partnerships between industry and academia hold promise to address this looming healthcare crisis.
Key Features of the Study:
This report provides an in-depth analysis of the global antibiotic resistance market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024–2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antibiotic resistance market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Melinta Therapeutics, Merck & Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc., Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceutials, Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva Threapeutics plc, NEMESIS BIOSCIENCE LTD.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antibiotic resistance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibiotic resistance market
Detailed Segmentation:
Global Antibiotic Resistance Market, By Drug Class
Oxazolidinones
Lipoglycopeptides
Tetracyclines
Cephalosporins
Others (Combination therapies, etc.)
Global Antibiotic Resistance Market, By Disease
cUTI (Complicated Urinary Tract Infections)
CDI (Clostridioides difficile Infection)
ABSSSI (Acute bacterial skin and skin structure infections)
HABP (Hospital-acquired bacterial pneumonia)
CABP (Community-acquired pneumonia)
cIAI (Complicated intra-abdominal infection)
Others (BSI (Bloodstream infection), etc.)
Global Antibiotic Resistance Market, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Antibiotic Resistance Market, By Region
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Top Companies in the Global Antibiotic Resistance Market:
Melinta Therapeutics
Merck & Co., Inc.
Allergan
Pfizer Inc.
Tetraphase Pharmaceutical, Inc.
Theravance Biopharma
WOCKHARDT
Entasis Threapeutics
Paratek Pharmaceutials, Inc.
Seres Therapeutics
Achaogen Inc.
Basilea Pharmaceutical Ltd.
Nabriva Threapeutics plc
NEMESIS BIOSCIENCE LTD.
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Disease
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Rising prevalence of infectious diseases
Advancement in antibiotic resistance diagnosis
Growing number of R&D activities
Key Highlights
Guidelines for the Temporary Staffing Agency & the Host Employer
Market Trends
PEST Analysis
Investments and Fundings
Mergers, Acquisitions, and Collaborations
Key Services Offered
Identification of Top Market Players
Nurse Staffing Dominance
Healthcare Spending by Country
4. Global Antibiotic Resistance Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Antibiotic Resistance Market, By Drug Class, 2019-2031, (US$ Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 – 2031
Segment Trends
Oxazolidinones
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Lipoglycopeptides
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Tetracyclines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Cephalosporins
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Others (Combination therapies, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
6. Global Antibiotic Resistance Market, By Disease, 2019-2031, (US$ Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 – 2031
Segment Trends
cUTI (Complicated Urinary Tract Infections)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
CDI (Clostridioides difficile Infection)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
ABSSSI (Acute bacterial skin and skin structure infections)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
HABP (Hospital-acquired bacterial pneumonia)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
CABP (Community-acquired pneumonia)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
cIAI (Complicated intra-abdominal infection)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Others (BSI (Bloodstream infection), etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
7. Global Antibiotic Resistance Market, By Distribution Channel, 2019-2031, (US$ Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 – 2031
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
8. Global Antibiotic Resistance Market, By Region, 2019-2031, (US$ Bn)
Introduction
Market Share Analysis, By Region, 2024 and 2031 (%)
Y-o-Y Growth Analysis, For Region, 2020 – 2031
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Bn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Company Profile
Melinta Therapeutics
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Merck & Co., Inc.
Allergan
Pfizer Inc.
Tetraphase Pharmaceutical, Inc.
TeamHealth
Theravance Biopharma
WOCKHARDT
Entasis Threapeutics
Paratek Pharmaceutials, Inc.
Seres Therapeutics
Achaogen Inc.
Basilea Pharmaceutical Ltd.
Nabriva Threapeutics plc
NEMESIS BIOSCIENCE LTD.
Analyst Views
10. Section
References
Research Methodology
About us
*Browse 35 market data tables and 37 figures on “Global Antibiotic Resistance Market” - Global forecast to 2031